Top

Acta Diabetologica

Published in:

Open Access 29-01-2024 | Type 2 Diabetes | Original Article

Association of serum CTRP4 levels with vascular endothelial function in patients with type 2 diabetes mellitus: CTRP4 ameliorating inflammation, proliferation and migration in human umbilical vein endothelial cells

Authors: Jie Gao, Mai Re YanMu Rouzi, Huihui Zhang, Xinghua Cai, Bilin Xu, Jun Lu, Tao Lei

Published in: Acta Diabetologica | Issue 5/2024

Abstract

Objective

We investigated the correlation between serum C1q/TNF-related protein 4 (CTRP4) level and flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM), and evaluated the biological effects of CTRP4 on human umbilical vein endothelial cells (HUVECs).

Methods

A group of 165 patients diagnosed with T2DM were included in this study. Endothelial function was measured with the examination of brachial artery FMD. ELISA kit was used to measure the levels of CTRP4 in serum. HUVECs were stimulated with recombinant CTRP4 protein to assess its biological functions.

Results

The levels of CTRP4 showed a significant variation among three groups based on FMD tertiles (p = 0.001). What’s more, FMD had a significant difference among three CTRP4 tertile groups (p < 0.05) and was negatively related to serum CTRP4 levels (r = −0.270, p < 0.001). In T2DM patients, logistic regression analysis demonstrated that CTRP4 was the primary influence factor of low FMD (p < 0.01). In receiver operating characteristic curve analysis, the area under the curve of CTRP4 for predicting low FMD was 0.66 (95%CI 0.58–0.75). When stimulated HUVECs with recombinant CTRP4 protein, we found that CTRP4 could concentration-dependently ameliorate proliferation and migration of HUVECs in wounding healing and transwell assay. This protein could also decrease the expression of IL-6 and TNF-α and promote the release of NO in HUVEC supernatants, with suppression of NF-κB and STAT3 phosphorylation.

Conclusions

Serum CTRP4 concentrations were negatively associated with FMD. CTRP4 alleviated proliferation, migration and inflammation in HUVECs through the suppression of NF-κB and STAT3 signaling pathways.

Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A et al (2022) Pathophysiology of atherosclerosis. Int J Mol Sci 23(6):3346. https://doi.org/10.3390/ijms23063346CrossRefPubMedPubMedCentral

Xu S, Ilyas I, Little PJ et al (2021) Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev 73(3):924–967. https://doi.org/10.1124/pharmrev.120.000096CrossRefPubMed

Williams SB, Cusco JA, Roddy MA et al (1996) Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27(3):567–574. https://doi.org/10.1016/0735-1097(95)00522-6CrossRefPubMed

Polovina MM, Potpara TS (2014) Endothelial dysfunction in metabolic and vascular disorders. Postgrad Med 126(2):38–53. https://doi.org/10.3810/pgm.2014.03.2739CrossRefPubMed

Celermajer DS, Sorensen KE, Gooch VM et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340(8828):1111–1115. https://doi.org/10.1016/0140-6736(92)93147-fCrossRefPubMed

de la Cruz-Ares S, Cardelo MP, Gutiérrez-Mariscal FM et al (2020) Endothelial dysfunction and advanced glycation end products in patients with newly diagnosed versus established diabetes: from the CORDIOPREV study. Nutrients 12(1):238. https://doi.org/10.3390/nu12010238CrossRefPubMedPubMedCentral

Li B, Zhang Q, Zhang H, Wang C, Xiu R (2020) Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension. Biosci Rep 40(5):BSR20200436. https://doi.org/10.1042/bsr20200436CrossRefPubMedPubMedCentral

Halcox JP, Donald AE, Ellins E et al (2009) Endothelial function predicts progression of carotid intima-media thickness. Circulation 119(7):1005–1012. https://doi.org/10.1161/circulationaha.108.765701CrossRefPubMed

Green DJ, Jones H, Thijssen D et al (2011) Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension 57(3):363–369. https://doi.org/10.1161/hypertensionaha.110.167015CrossRefPubMed

10.

Huang NK, Bůžková P, Matthan NR et al (2021) Serum non-esterified fatty acids, carotid artery intima-media thickness and flow-mediated dilation in older adults: the cardiovascular health study (CHS). Nutrients 13(9):3052. https://doi.org/10.3390/nu13093052CrossRefPubMedPubMedCentral

11.

Wong GW, Wang J, Hug C et al (2004) A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci USA 101(28):10302–10307. https://doi.org/10.1073/pnas.0403760101CrossRefPubMedPubMedCentral

12.

Kishore U, Gaboriaud C, Waters P et al (2004) C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol 25(10):551–561. https://doi.org/10.1016/j.it.2004.08.006CrossRefPubMed

13.

Wong GW, Krawczyk SA, Kitidis-Mitrokostas C et al (2009) Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. Faseb J 23(1):241–258. https://doi.org/10.1096/fj.08-114991CrossRefPubMedPubMedCentral

14.

Peterson JM, Aja S, Wei Z et al (2012) CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. J Biol Chem 287(2):1576–1587. https://doi.org/10.1074/jbc.M111.278333CrossRefPubMed

15.

Jeon JH, Kim KY, Kim JH et al (2008) A novel adipokine CTRP1 stimulates aldosterone production. Faseb J 22(5):1502–1511. https://doi.org/10.1096/fj.07-9412comCrossRefPubMed

16.

Schäffler A, Buechler C (2012) CTRP family: linking immunity to metabolism. Trends Endocrinol Metab 23(4):194–204. https://doi.org/10.1016/j.tem.2011.12.003CrossRefPubMed

17.

Fadaei R, Moradi N, Baratchian M et al (2016) Association of C1q/TNF-related protein-3 (CTRP3) and CTRP13 serum levels with coronary artery disease in subjects with and without type 2 diabetes mellitus. PLoS ONE 11(12):e0168773. https://doi.org/10.1371/journal.pone.0168773CrossRefPubMedPubMedCentral

18.

Fadaei R, Moradi N, Kazemi T et al (2019) Decreased serum levels of CTRP12/adipolin in patients with coronary artery disease in relation to inflammatory cytokines and insulin resistance. Cytokine 113:326–331. https://doi.org/10.1016/j.cyto.2018.09.019CrossRefPubMed

19.

Moradi N, Fadaei R, Emamgholipour S et al (2018) Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease. PLoS ONE 13(1):e0192159. https://doi.org/10.1371/journal.pone.0192159CrossRefPubMedPubMedCentral

20.

Muendlein A, Leiherer A, Saely C et al (2019) The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events. Atherosclerosis 286:1–6. https://doi.org/10.1016/j.atherosclerosis.2019.04.222CrossRefPubMed

21.

Shen Y, Li C, Zhang RY et al (2017) Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells. Int J Cardiol 228:129–136. https://doi.org/10.1016/j.ijcard.2016.11.034CrossRefPubMed

22.

Wang J, Hang T, Cheng XM et al (2015) Associations of C1q/TNF-related protein-9 levels in serum and epicardial adipose tissue with coronary atherosclerosis in humans. Biomed Res Int 2015:971683. https://doi.org/10.1155/2015/971683CrossRefPubMedPubMedCentral

23.

Byerly MS, Petersen PS, Ramamurthy S et al (2014) C1q/TNF-related protein 4 (CTRP4) is a unique secreted protein with two tandem C1q domains that functions in the hypothalamus to modulate food intake and body weight. J Biol Chem 289(7):4055–4069. https://doi.org/10.1074/jbc.M113.506956CrossRefPubMed

24.

Wang L (2017) CTRP4: a new member of the adipocytokine family. Cell Mol Immunol 14(10):868–870. https://doi.org/10.1038/cmi.2017.83CrossRefPubMedPubMedCentral

25.

Li Y, Ye L, Jia G et al (2020) C1q/TNF-related protein 4 induces signal transducer and activator of transcription 3 pathway and modulates food intake. Neuroscience 429:1–9. https://doi.org/10.1016/j.neuroscience.2019.12.039CrossRefPubMed

26.

Cao L, Tan W, Chen W et al (2021) CTRP4 acts as an anti-inflammatory factor in macrophages and protects against endotoxic shock. Eur J Immunol 51(2):380–392. https://doi.org/10.1002/eji.202048617CrossRefPubMed

27.

Luo Y, Wu X, Ma Z et al (2016) Expression of the novel adipokine C1qTNF-related protein 4 (CTRP4) suppresses colitis and colitis-associated colorectal cancer in mice. Cell Mol Immunol 13(5):688–699. https://doi.org/10.1038/cmi.2016.16CrossRefPubMedPubMedCentral

28.

Sarver DC, Stewart AN, Rodriguez S et al (2020) Loss of CTRP4 alters adiposity and food intake behaviors in obese mice. Am J Physiol Endocrinol Metab 319(6):E1084-e1100. https://doi.org/10.1152/ajpendo.00448.2020CrossRefPubMedPubMedCentral

29.

Gao J, Lu J, Qiu J et al (2022) C1q tumor necrosis factor-related protein 4 is associated with coronary artery disease in patients with type 2 diabetes. J Diabetes Investig. https://doi.org/10.1111/jdi.13842CrossRefPubMedPubMedCentral

30.

Williams B, Mancia G, Spiering W et al (2018) ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39(33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339CrossRefPubMed

31.

American Diabetes Association (2021) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes care 44(Supplement 1):S15–S33. https://doi.org/10.2337/dc21-S002CrossRef

32.

Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14(2):88–98. https://doi.org/10.1038/nrendo.2017.151CrossRefPubMed

33.

Henning RJ (2018) Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol 14(6):491–509. https://doi.org/10.2217/fca-2018-0045CrossRefPubMed

34.

Villano A, Mencarelli E, Melita V et al (2020) Endothelial dysfunction and cardiovascular outcome in asymptomatic patients with type 2 diabetes: a pilot study. Diabetes Metab Res Rev 36(1):e3215. https://doi.org/10.1002/dmrr.3215CrossRefPubMed

35.

Ras RT, Streppel MT, Draijer R et al (2013) Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol 168(1):344–351. https://doi.org/10.1016/j.ijcard.2012.09.047CrossRefPubMed

36.

Lundman P, Eriksson MJ, Stühlinger M et al (2001) Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38(1):111–116. https://doi.org/10.1016/s0735-1097(01)01318-3CrossRefPubMed

37.

Henry RM, Ferreira I, Kostense PJ et al (2004) Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not: the Hoorn study. Atherosclerosis 174(1):49–56. https://doi.org/10.1016/j.atherosclerosis.2004.01.002CrossRefPubMed

38.

Ozaki K, Hori T, Ishibashi T et al (2010) Effects of chronic cigarette smoking on endothelial function in young men. J Cardiol 56(3):307–313. https://doi.org/10.1016/j.jjcc.2010.07.003CrossRefPubMed

39.

Walther G, Obert P, Dutheil F et al (2015) Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross-sectional study. Arterioscler Thromb Vasc Biol 35(4):1022–1029. https://doi.org/10.1161/atvbaha.114.304591CrossRefPubMed

40.

Zehr KR, Walker MK (2018) Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: a review. Prostaglandins Other Lipid Mediat 134:131–140. https://doi.org/10.1016/j.prostaglandins.2017.07.005CrossRefPubMed

41.

Pronko TP, Zinchuk VV (2009) Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension. Clin Physiol Funct Imaging 29(3):170–176. https://doi.org/10.1111/j.1475-097X.2008.00852.xCrossRefPubMed

42.

Ding H, Liu S, Zhao KX et al (2022) Comparative efficacy of antihypertensive agents in flow-mediated vasodilation of patients with hypertension: network meta-analysis of randomized controlled trial. Int J Hypertens 2022:2432567. https://doi.org/10.1155/2022/2432567CrossRefPubMedPubMedCentral

43.

Radenković M, Stojanović M, Prostran M (2019) Calcium channel blockers in restoration of endothelial function: systematic review and meta-analysis of randomized controlled trials. Curr Med Chem 26(29):5579–5595. https://doi.org/10.2174/0929867325666180713144806CrossRefPubMed

44.

Shahin Y, Khan JA, Samuel N et al (2011) Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 216(1):7–16. https://doi.org/10.1016/j.atherosclerosis.2011.02.044CrossRefPubMed

45.

Kähönen M, Arvola P, Mäkynen H et al (1996) Antihypertensive therapy and arterial function in experimental hypertension. Gen Pharmacol 27(2):221–238. https://doi.org/10.1016/0306-3623(95)02015-2CrossRefPubMed

46.

Dai Y, Zhou J, Niu L et al (2022) Increased serum C1q/TNF-related protein 4 concentration in patients with acute coronary syndrome. Clin Chim Acta 524:187–191. https://doi.org/10.1016/j.cca.2021.11.015CrossRefPubMed

47.

Liu Z, Lu J, Zhang D et al (2021) Decreased serum C1Q/TNF-related protein 4 concentrations are associated with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 12:20420188211059884. https://doi.org/10.1177/20420188211059884CrossRefPubMedPubMedCentral

48.

Li Q, Wang L, Tan W et al (2011) Identification of C1qTNF-related protein 4 as a potential cytokine that stimulates the STAT3 and NF-κB pathways and promotes cell survival in human cancer cells. Cancer Lett 308(2):203–214. https://doi.org/10.1016/j.canlet.2011.05.005CrossRefPubMed

49.

Ye L, Jia G, Li Y et al (2021) C1q/TNF-related protein 4 restores leptin sensitivity by downregulating NF-κB signaling and microglial activation. J Neuroinflamm 18(1):159. https://doi.org/10.1186/s12974-021-02167-2CrossRef

50.

Cao L, Deng J, Chen W et al (2023) CTRP4/interleukin-6 receptor signaling ameliorates autoimmune encephalomyelitis by suppressing Th17 cell differentiation. J Clin Invest. https://doi.org/10.1172/jci168384CrossRefPubMedPubMedCentral

51.

Martincuks A, Andryka K, Küster A et al (2017) Nuclear translocation of STAT3 and NF-κB are independent of each other but NF-κB supports expression and activation of STAT3. Cell Signal 32:36–47. https://doi.org/10.1016/j.cellsig.2017.01.006CrossRefPubMed

Title: Association of serum CTRP4 levels with vascular endothelial function in patients with type 2 diabetes mellitus: CTRP4 ameliorating inflammation, proliferation and migration in human umbilical vein endothelial cells
Authors: Jie Gao
Mai Re YanMu Rouzi
Huihui Zhang
Xinghua Cai
Bilin Xu
Jun Lu
Tao Lei
Publication date: 29-01-2024
Publisher: Springer Milan
Keyword: Type 2 Diabetes
Published in: Acta Diabetologica / Issue 5/2024
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-023-02228-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2024

Association between a polygenic lipodystrophy genetic risk score and diabetes risk in the high prevalence Maltese population

Use of teplizumab in children and adolescents at risk of type 1 diabetes: perspectives of parents and caregivers from an Italian Pediatric Diabetes Center

Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes: the Hypo-RESOLVE hypoglycaemic clamp study

Continuous improvement of quality of care in pediatric diabetes: the ISPED CARD clinical registry

Association of carotid atherosclerosis markers with all-cause and cardiovascular disease–specific mortality in persons with type 2 diabetes: a causal mediation analysis with glucose variation

Association of pro-inflammatory cytokines, adipokines and hepatokine with incident diabetes in India: a nested case–control study within CARRS cohort

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage